03:17 PM EST - Nuvo Research Inc. : announced that it has reached a full settlement with Mallinckrodt Inc. of Nuvo's claims and Mallinckrodt's counterclaim relating to Nuvo's license to Mallinckrodt of the right to market and sell Pennsaid® and Pennsaid 2% in the United States. Under the terms of the settlement agreement, Mallinckrodt will return all U.S. rights to Pennsaid and Pennsaid 2% to Nuvo after a brief transition period and pay $10 million U.S. Nuvo Research Inc.
shares T.NRI are trading up $0.01 at $3.90.
